The Therapeutic Efficacy of Carprofen (Rimadyl-V™) in 209 Clinical Cases of Canine Degenerative Joint Disease

R. H. Holtsinger; R. B. Parker; B. S. Beale; R. L. Friedman

doi:10.1055/s-0038-1633101

Veterinary and Comparative Orthopaedics and Traumatology, Table of Contents

Vet Comp Orthop Traumatol 1992; 05(04): 140-144
DOI: 10.1055/s-0038-1633101

Clinical Report

Schattauer GmbH

The Therapeutic Efficacy of Carprofen (Rimadyl-V™) in 209 Clinical Cases of Canine Degenerative Joint Disease

Authors

R. H. Holtsinger

¹Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA
R. B. Parker

¹Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA
B. S. Beale

¹Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA
R. L. Friedman

¹Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA

Abstract

Summary

Carprofen (D,L-6-chlor-alphamethylcarbazole-2-acetic acid) is a nonsteroidal anti-inflammatory drug with demonstrated therapeutic activity in the relief of clinical signs of degenerative joint disease in laboratory animal models and in human trials. The double-blind clinical study, reported herein, compared the therapeutic efficacy of carprofen with that of a placebo, in the acute relief of clinical canine degenerative joint disease. Twohundred and nine cases were collected from 10 studies in three geographic regions of the USA. The results of logistic analysis showed that dogs treated with carprofen were 24.8 times more likely to receive a positive evaluation by the veterinarian than those treated with a placebo (p <0.01). The odds of showing improvement, when evaluated by the owners, were 13.4 times greater than placebo (p <0.01). The evaluation from the veterinarian and the owner had excellent agreement (Kappa = 0.997) for dogs treated with carprofen and good agreement (Kappa = 0.667) for those treated with the placebo. Regional differences in response rate were not found in these studies. This trial demonstrated that carprofen is efficacious, across geographic regions, in the acute relief of clinical signs associated with canine degenerative joint disease.

Carprofen is a new anti-inflammatory drug (NSAID) with analgesic potency. Side effects reported are few. Dogs with degenerative joint disease (DSD) treated with carprofen were 24.8 times more likely to respond favourably than placebo-treated dogs (p <0.01). This study concluded that carprofen is an effective NSAID in relieving the clinical signs of DSD in dogs.

Keywords

Carprofen - non-steroidal anti-inflammatory drugs - canine - degenerative joint disease

Full Text

References

REFERENCES
1 O’Brien WM, Bagby GF. Carprofen: A new nonsteroidal anti-inflammatory drug. Pharmacotherapy 1987; 7 (Suppl. 01) 16-24.
2 Brogden RN. Nonsteroidal anti-inflammatory analgesics other than salicylates. Drugs 1986; 32 (Suppl. 04) 27-45.
3 Randall LO, Barutl H. Analgesic and anti-inflammatory activity of 6-chloro-alphamethylcarbazole-2-acetic acid (C-S720). Arch Int Pharmacodyn Ther 1976; 220: 94-114.
4 Cozzolino F, Costa L, Marasco F. The clinical efficacy and tolerance of a new anti-inflammatory agent, carprofen, in osteoarthritis. Comparative double-blind study with naproxen. Clin Ter 1983; 106 (Suppl. 06) 435-9.
5 Pipino F, Busetto M, Franchin F, Punzi L. et al. Treatment of osteoarthrosis with a new nonsteroidal anti-inflammatory agent, carprofen. Clin Ter 1984; 108 (Suppl. 05) 405-10.
6 Stein GH, Dickey RA, Cohn PD. et al. Controlled comparison of carprofen and aspirin in osteoarthritis of the knee. Curr Thcrap Res 1983; 33 (Suppl. 03) 415-22.
7 Jensen EM, Fossgreen J, Kirchheiner B, Kryger J. et al. Treatment of rheumatoid arthritis with carprofen (Imadyl®) or indomethacin: A randomized multicentre trial. Curr Therap Res 1980; 28 (Suppl. 06) 882-7.
8 Isomaki H, Martio J, Kaarela K. et al. Comparison of the analgesic effect of ten nonsteroidal anti-inflammatory drugs. Br J Rheumatol 1984; 23: 61-5.
9 Jenkins WL. Pharmacologic aspects of analgesic drugs in animals: An overview. J Am Vet Med Assoc 1987; 191: 1231-40.
10 Kore AM. Toxicology of nonsteroidal anti-inflammatory drugs. Vet Clin N Am Small Anim Pract 1990; 20 (Suppl. 02) 419-30.
11 Wallace MS, Zawie DA, Garvey MS. Gastric ulceration in the dog secondary to the use of nonsteroidal anti-inflammatory drugs. J Am Anim Hosp Assoc 1990; 26: 467-72.
12 Gilmore MA, Walshaw R. Naproxen-induced toxicosis in a dog. J Am Vet Med Assoc 1987; 191: 1431-2.
13 Spyridakis LK, Bacia JJ, Barsanti JA. et al. Ibuprofen toxicosis in a dog. J Am Vet Med Assoc 1986; 188: 918-9.
14 Ewing GO. Indomethacin-associated gastrointestinal hemorrhage in a dog. J Am Vet Med Assoc 1972; 161: 1665-8.
15 Roudebush P, Morse GE. Naproxen toxicosis in a dog. J Am Vet Med Assoc 1981; 179: 805-6.
16 Daehler MH. Transmural pyloric perforation associated with naproxen administration in a dog. J Am Vet Med Assoc 1986; 189: 694-5.
17 Gorman MP. Hoffman-LaRoche Laboratories; Personal communication, unpublished data on file. Nutley, NJ.:
18 Fleiss JL. Statistical Methods for Rates and Proportion. New York: John Wiley and Sons; 1981: 217-20.
19 Tursi A, Loria MP, Specchia G. et al. In vitro studies of anti-inflammatory activity of carprofen. Eur J Rheumatol Inflammat 1982; 5: 488-91.
20 Strub KM, Aeppli L, Muller RKM. Pharmacological properties of carprofen. Eur J Rheumatol Inflamm 1982; 5: 478-87.
21 Gaut ZN, Barutl H, Randall LO. et al. Stereoisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase. Prostaglandins 1975; 10: 59-63.
22 Konturek SJ, Kwiecicn N, Obtulowicz W. et al. Effect of carprofen and indomethacin on gastric function, mucosal integrity, and generation of prostaglandins in men. Hepatogastroenterology 1982; 29: 267-70.
23 Rider JA, Dickey RA. Comparative fecal blood loss - aspirin vs. carprofen. Lancet. 1977: 22.
24 Rubin SI. NSAIDs, prostaglandins, and the kidney. J Am Vet Med Assoc 1986; 188: 1065-8.
25 Holazo AA, Chen SS, McMahon FG. et al. The influence of liver dysfunction on the pharmacokinetics of carprofen. J Clin Pharmacol 1985; 25: 109-14.
26 Seaman WE, Ishak KG, Plotz PH. Aspirin-induced hepatic toxicity in patients with systemic lupus erythematosus. Ann Intern Med 1974; 80: 1-8.
27 Rubio F, Seawall S, Pocelinko R. et al. Metabolism of carprofen, a nonsteroidal anti-inflammatory agent, in rats, dogs, and humans. J Pharm Sci 1980; 69 (Suppl. 11) 1245-53.